Bristol-Myers Squibb (NY:BMY)

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts ↗

January 31, 2025

Via Benzinga

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

January 31, 2025

Deep Dive Into Bristol-Myers Squibb Stock: Analyst Perspectives (9 Ratings) ↗

January 28, 2025

Via Benzinga

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? ↗

January 10, 2025

Via Benzinga

January 09, 2025

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

January 31, 2025

3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average ↗

January 29, 2025

The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech.

Topics Stocks

Biotech And Healthcare Stocks Poised For Gains Ahead ↗

January 27, 2025

Via Talk Markets

Topics ETFs Stocks / Equities

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 27, 2025

Via Benzinga

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? ↗

December 31, 2024

Via Benzinga

Peering Into Bristol-Myers Squibb's Recent Short Interest ↗

December 31, 2024

Via Benzinga

2 High-Yield Dividend Stocks to Buy Early in 2025 ↗

December 31, 2024

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

January 25, 2025

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗

January 17, 2025

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Via Benzinga

Topics Government

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

January 22, 2025

From FN Media Group LLC

Via GlobeNewswire

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal ↗

January 13, 2025

Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.

Via Benzinga

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

January 13, 2025

From Arsenal Biosciences

Via GlobeNewswire

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗

January 09, 2025

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Via Benzinga

Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators ↗

January 08, 2025

Alger launched its INVN ETF, with holdings including BioMarin, Teradata, and Bristol-Myers Squibb.

Via Benzinga

Topics ETFs

Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

January 08, 2025

Via Benzinga

3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade ↗

January 04, 2025

Vera Bradley faces shareholder pressure for underperformance, while acquisitions and restructurings define this week's deal landscape.

Deal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party City ↗

January 03, 2025

Via Benzinga

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

January 03, 2025

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

December 27, 2024

Investors are keeping a close eye on BRISTOL-MYERS SQUIBB CO (NYSE:BMY) as it boasts an impressive technical rating of 7 out of 10, signaling a possible breakout.

Exploring BRISTOL-MYERS SQUIBB CO's Technical Signals and Breakout Potential. ↗

December 27, 2024

Via Chartmill

Schwab US Dividend Equity ETF Reverses In December: What's Going On? ↗

December 23, 2024

The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund:

Via Benzinga

Topics ETFs

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

December 23, 2024